All products are intended solely for collector's purposes!
It is NOT possible to use chemical substances as medicine, medicine, active substance, medical aid, cosmetic product, substance for the production of a cosmetic product...
Also not as a substance for human consumption, ie as a food or nutritional supplement or in any other similar way on humans or animals.
18+ All customers MUST be at least 18 years of age to purchase our products.

Dihexa 10mg – 30 capsules

128.00

Availability: 43 in stock

3 Products -5%
121.60 € /pc
6 Products -10%
115.20 € /pc
8 Products -15%
108.80 € /pc
Third-Party Tested

Laboratory test for this product

View the certificate of analysis and laboratory verification for this product.

Dihexa 10 mg — 30 oral research capsules. Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is among the most strikingly potent synaptogenic molecules ever characterized in academic neuropharmacology. Developed in the laboratory of Joseph Harding at Washington State University as part of a program optimizing angiotensin-IV-derived neurotrophic peptides, Dihexa is approximately seven orders of magnitude (~10,000,000-fold) more potent than BDNF in inducing functional synaptogenesis between hippocampal neurons in vitro — a figure that, even discounted aggressively, places it in a category of its own. Its proposed primary mechanism is augmentation of hepatocyte growth factor / c-Met signaling, the same axis that drives neuronal repair after stroke and traumatic injury.

RESEARCH USE ONLY  ·  Not for human or veterinary use. For laboratory and collector purposes only.

Purity
≥ 98 % (HPLC) — third-party tested, CoA on file
Form
Research capsules
Content
10 mg Dihexa per capsule
Total
30 capsules per bottle (300 mg total)
Packaging
Sealed bottle with tamper-evident closure
Storage
Room temperature, dry, protected from light
Molecular formula
C₂₆H₄₂N₄O₅
Molecular weight
≈ 490.64 g·mol⁻¹
IUPAC / structure
N-Hexanoic-tyrosine-isoleucine-(6) aminohexanoic amide (modified angiotensin-IV-derived peptide)
CAS number
1401708-83-5
Synonyms
PNB-0408; angiotensin-IV-derived synaptogenic peptide

Research Overview

Dihexa is the most pharmacologically optimized member of the angiotensin-IV-derived neurotrophic peptide family — a research program initiated by the Harding group at Washington State University after the discovery that angiotensin IV itself enhances memory and synaptic plasticity in rodent models [1]. Successive structural modifications, principally to confer oral bioavailability and CNS penetration, produced Dihexa: an orally active, BBB-permeant peptidomimetic with no measurable angiotensin receptor activity but extraordinary synaptogenic potency [1,2]. In primary hippocampal neuron cultures, Dihexa induces formation of functional excitatory synapses at sub-femtomolar concentrations — making it approximately seven orders of magnitude more potent than BDNF and several orders of magnitude more potent than any other known synaptogenic molecule [1]. The proposed primary mechanism involves augmentation of hepatocyte growth factor (HGF) / c-Met receptor signaling, with downstream activation of MAPK, PI3K-Akt and the canonical synaptic-protein-synthesis machinery [2]. In aged rats with established scopolamine-induced or natural age-related memory deficits, oral Dihexa rescues spatial-memory performance to young-adult levels [3]. The compound has emerged as a flagship research tool in the synaptogenesis-driven approach to neurodegenerative disease.

Primary Research Areas

  • Synaptogenesis pharmacology — approximately seven orders of magnitude more potent than BDNF in inducing functional synapse formation in hippocampal neuron cultures [1].
  • HGF / c-Met receptor signaling — the principal proposed mechanism, providing a clean pharmacological probe of HGF-mediated neuronal repair pathways [2].
  • Cognitive rescue in aged rodent models — restores spatial memory in aged rats and in scopolamine-induced cognitive deficit models at orally relevant doses [3].
  • Alzheimer’s and age-related cognitive decline research — investigated as a synaptogenesis-based alternative to amyloid-clearance and AChE-inhibitor strategies [1,3].
  • Stroke and TBI repair models — of interest in research on post-injury synaptic remodeling and functional recovery [2].

References

  1. McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141–154.
  2. Benoist CC, Wright JW, Zhu M, et al. Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogs. J Pharmacol Exp Ther. 2011;339(1):35–44.
  3. Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases. Prog Neurobiol. 2015;125:26–46.

Find out what benefits peptides have

Discover how peptides can boost recovery, improve skin health, increase energy and support overall performance. Explained simply and clearly in this short video.

Why Limitless Biochem?

Limitless BioChem is a trusted supplier of research compounds. Our products meet strict quality standards and are compliant with EU requirements. We focus on the safe and reliable supply of peptides and pure compounds intended exclusively for research or collector purposes.

This product is not intended for human or veterinary use. It is for collection or research purposes only. It cannot be used as food, dietary supplement or medicine! The information provided in the text on this page is for educational purposes only and does not constitute medical or other advice.

RELATED PRODUCTS

Scroll to Top
Cart • 0
You're 500.00 away from FREE Shipping!
FREE
Shipping

Your cart is empty

AI
Limitless AI help Choose question type

How can I help you?